CA2270913A1 - Recepteur tr2 du facteur de necrose tumorale chez l'homme - Google Patents

Recepteur tr2 du facteur de necrose tumorale chez l'homme

Info

Publication number
CA2270913A1
CA2270913A1 CA002270913A CA2270913A CA2270913A1 CA 2270913 A1 CA2270913 A1 CA 2270913A1 CA 002270913 A CA002270913 A CA 002270913A CA 2270913 A CA2270913 A CA 2270913A CA 2270913 A1 CA2270913 A1 CA 2270913A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
acid sequence
polypeptide
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002270913A
Other languages
English (en)
Other versions
CA2270913C (fr
Inventor
Jian Ni
Craig A. Rosen
Reiner L. Gentz
Sally Doreen Patricia Lyn
Mark Robert Hurle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2270913A1 publication Critical patent/CA2270913A1/fr
Application granted granted Critical
Publication of CA2270913C publication Critical patent/CA2270913C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux membres de la famille des récepteurs du facteur de nécrose tumorale. L'invention concerne des molécules isolées d'acide nucléique codant un récepteur TR2 humain et deux variantes épissées dudit récepteur. L'invention concerne aussi des polypeptides TR2, ainsi que des vecteurs, cellules hôtes et procédés de recombinaison permettant de produire lesdits éléments. L'invention concerne également des méthodes de sélection permettant d'identifier des agonistes et antagonistes de l'activité du récepteur TR2. L'invention concerne en outre des méthodes diagnostiques pour dépister des pathologies liées à l'expression aberrante de récepteurs TR2, ainsi que des méthodes thérapeutiques pour traiter des pathologies liées à une prolifération ou différenciation aberrante de cellules exprimant des récepteurs TR2.
CA2270913A 1996-10-30 1996-10-30 Recepteur tr2 du facteur de necrose tumorale chez l'homme Expired - Fee Related CA2270913C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/018540 WO1998018824A1 (fr) 1996-10-30 1996-10-30 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Publications (2)

Publication Number Publication Date
CA2270913A1 true CA2270913A1 (fr) 1998-05-07
CA2270913C CA2270913C (fr) 2011-05-24

Family

ID=22256163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2270913A Expired - Fee Related CA2270913C (fr) 1996-10-30 1996-10-30 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Country Status (4)

Country Link
EP (1) EP0961782A4 (fr)
JP (1) JP2001502912A (fr)
CA (1) CA2270913C (fr)
WO (1) WO1998018824A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
AU5804499A (en) * 1998-09-03 2000-03-27 Millennium Pharmaceuticals, Inc. Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
US6287808B1 (en) 1998-09-03 2001-09-11 Millennium Pharmaceuticals, Inc. Molecules of the herpesvirus-entry-mediator-related protein family and uses thereof
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
EP1263788A2 (fr) * 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification d'un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l'assemblage et la fonction du recepteur de pre-ligand
WO2001079496A2 (fr) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand pour mediateur d'entree du virus herpes simplex et procedes de mise en oeuvre
EP1674575B1 (fr) * 2000-04-12 2010-10-06 La Jolla Institute For Allergy And Immunology Ligand du médiateur d'accès du virus de l'herpès simplex et procédés d'utilisation
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5464938A (en) * 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
WO1996034095A1 (fr) * 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Recepteurs du facteur de necrose tumorale chez l'homme

Also Published As

Publication number Publication date
WO1998018824A1 (fr) 1998-05-07
JP2001502912A (ja) 2001-03-06
WO1998018824A9 (fr) 1999-09-30
EP0961782A4 (fr) 2003-07-16
EP0961782A1 (fr) 1999-12-08
CA2270913C (fr) 2011-05-24

Similar Documents

Publication Publication Date Title
US6844168B1 (en) Compositions comprising polynucleotides encoding human fibroblast growth factor receptor and uses thereof
CA2343655A1 (fr) Proteine de type recepteur d'interleukine 17
WO1992014748A1 (fr) Identification d'un nouveau gene humain recepteur de tyrosine kinase
CA2270913A1 (fr) Recepteur tr2 du facteur de necrose tumorale chez l'homme
George Jr et al. Genomic organization of the human skeletal muscle sodium channel gene
AU7608898A (en) Ntn-2 member of tnf ligand family
WO2004096980A2 (fr) Nouveaux polynucleotides codant pour des polypeptides solubles et methodes faisant appel a ces derniers
JP2002522041A5 (fr)
CA2321089A1 (fr) Homologue humain de la proteine ?fused ? de drosophile
CA2323776A1 (fr) Analogue de chaine gamma commune de recepteur de cytokine
CA2302808A1 (fr) 50 proteines secretees d'origine humaine
JP2003525566A (ja) １２５個のヒト分泌タンパク質
US20020160451A1 (en) Novel orphan receptors
JP2000510690A (ja) 哺乳類混合リンパ球受容体、ケモカイン受容体（ｍｍｌｒ―ｃｃｒ）
AU628895B2 (en) Cloning and expression of a protein which modulates cellular response to type i interferon
AU663216B2 (en) Bone-related cadherin-like protein and process for its production
CA2241786A1 (fr) Nouvelles proteines kinases activees par l'amp
AU748167B2 (en) Novel nucleic acid and polypeptide
CN101309930A (zh) ErbB配体的剪接变体、其组合物及其用途
US6384205B1 (en) Metabotropic glutamate receptor 4 nucleic acid
AU753400C (en) Orphan receptors
WO1998022586A2 (fr) POLYHOMEOTIQUE HUMAIN 2 (hph2) AGISSANT COMME SUPPRESSEUR DE TUMEUR
US6207413B1 (en) Nucleic acids encoding novel orphan cytokine receptors
CA2236001C (fr) Ligands biologiquement actifs de la famille des eph
I’lrk et al. Surface receptors for soluble ligands

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151030